|LETTER TO EDITOR
|Year : 2021 | Volume
| Issue : 3 | Page : 571-572
Authors' reply to Pimple et al., Ghafur, and Potter
Ullas Batra1, Shrinidhi Nathany2, Mansi Sharma1, Nitin Bansal3
1 Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
2 Department of Molecular Diagnostics, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
3 Department of Infectious Diseases, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
|Date of Submission||30-Aug-2021|
|Date of Decision||30-Aug-2021|
|Date of Acceptance||08-Sep-2021|
|Date of Web Publication||08-Oct-2021|
Sector 5 Rohini, Sir Chhotu Ram Marg, New Delhi - 110 085
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Batra U, Nathany S, Sharma M, Bansal N. Authors' reply to Pimple et al., Ghafur, and Potter. Cancer Res Stat Treat 2021;4:571-2
We thank Pimple et al., Ghafur, and Potter for their expert opinions on our article titled “COVID-19 vaccination status in Indian patients with cancer: An observational study.” The COVID-19 pandemic has ushered in a new era in the lives the general public, impacting the health-care fraternity the most. Until the development of the vaccine, non-pharmaceutical measures including masking, social distancing, and nationwide lockdowns were employed to contain the disease, however, most countries have exhibited a two-wave pattern of the pandemic in the last 2 years.
The vaccination drive in India is in full swing; however, due to lack of objective evidence from trials in patients with cancer, we experience hesitancy in this subgroup of our patients, who are at the highest risk of not only contracting the infection but also for related morbidity and mortality.[6.7] The two vaccines, Covaxin and Covishield, currently being administered in India have shown good results in preventing severe disease, as has also been highlighted in our experience. The main reason for hesitancy towards vaccination in this subgroup of patients as highlighted by Noronha et al., is fear. As oncologists, it is important that we teach and counsel our patients against this fear with the evidence generated through our experiences.
Although retrospective and single center in nature, ours and a similar experience reported by Noronha et al. have unearthed glaring disparities in this group. These are currently the only two studies from India highlighting the need to educate patients with cancer about the benefits of vaccination in the prevention of severe disease and for uninterrupted cancer-directed therapy.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Pimple S, Mishra G. Need for a national consortium of clinical registries of cancer and COVID-19 for vaccine surveillance. Cancer Res Stat Treat 2021;4:570-1. [Full text]
Ghafur A. We need to tackle vaccine hesitancy in our patients with cancer. Cancer Res Stat Treat 2021;4:564-5. [Full text]
Potter DA. The oncologist as COVID-19 vaccine teacher and logistician: A pathway to better outcomes. Cancer Res Stat Treat 2021;4:567-8. [Full text]
Shrivastava SR, Shrivastava PS. Impact of the COVID-19 pandemic on patients with cancer and cancer survivors: A narrative review. Cancer Res Stat Treat 2021;4:315-20. [Full text]
Kulkarni T, Sharma P, Pande P, Agrawal R, Rane S, Mahajan A. COVID-19: A review of protective measures. Cancer Res Stat Treat 2020;3:244-53. [Full text]
Bansal N, Ghafur A. COVID-19 in oncology settings. Cancer Res Stat Treat 2020;3 Suppl S1:13-4.
Noronha V, Abraham G, Bondili SK, Rajpurohit A, Menon RP, Gattani S, et al.
COVID-19 vaccine uptake and vaccine hesitancy in Indian patients with cancer: A questionnaire-based survey. Cancer Res Stat Treat 2021;4:211-8. [Full text]
Batra U, Nathany S, Bansal N, Sharma M. COVID-19 vaccination status in Indian patients with cancer: An observational study. Cancer Res Stat Treat 2021;4:219-23. [Full text]